CereScan CEO John Kelley accepted into Forbes Technology Council

John Kelley, CEO and Chairman of CereScan, has been accepted into the Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs and technology executives.

Kelley joins other Forbes Tech Council members, who are hand-selected, to become part of a curated network of successful peers and get access to a variety of exclusive benefits and resources, including the opportunity to submit thought leadership articles and short tips on industry-related topics for publishing on Forbes.com.

Forbes Councils combines an innovative, high-touch approach to community management perfected by the team behind Young Entrepreneur Council (YEC) with the extensive resources and global reach of Forbes. As a result, Forbes Council members get access to the people, benefits and expertise they need to grow their businesses — and a dedicated member concierge who acts as an extension of their own team, providing personalized one-on-one support.

“I’m thrilled to join this prestigious technology community,”  says Kelley. “I look forward to contributing to the council, collaborating with other members and further reinforcing CereScan’s leadership role in the techmed industry.”

CereScan® is the leading provider of neuro-diagnostics solutions and its medical analytics platform CereMetrix®, is set to change the way brain disorders are evaluated and diagnosed. Through the use of its patented, statistically-correlated, normative and scalable medical database, CereMetrix® is designed to aid in the diagnosis and treatment of the human brain.

Scott Gerber, founder of Forbes Councils, says, “We are honored to welcome John Kelley into the community. Our mission with Forbes Councils is to curate successful professionals from every industry, creating a vetted, social capital-driven network that helps every member make an even greater impact on the business world.”

Esports Entertainment Group Signs Affiliate Marketing Agreements with Additional 34 Esports Teams, Bringing Total To 134 Esports Teams

Esports Entertainment Group Signs Affiliate Marketing Agreements with Additional 34 Esports Teams, Bringing Total To 134 Esports Teams

The addition of these 34 esports teams brings the total number of esports team affiliates to 134 since the Company’s first announcement on April 5th, representing a major milestone for Esports Entertainment Group, as well as, a major event within the esports world where no other esports wagering site has ever signed an Affiliate Marketing Agreement with an esports team.

KromaTiD in the News

NEW YORK (GenomeWeb) – Kromatid said today that it has received a Fast-Track Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute to further develop its proprietary single-cell structural genomics platform.

The $206,597 grant was awarded on Aug. 1 and expires at the end of the year.

The automated, whole-genome directional genomic hybridization (dGH) platform is capable of measuring de novo random, low-frequency, and complex structural variations in individual cells, and provides quantitative structural variation data that cannot be measured through any other method, the company said. 

The current dGH platform was developed using an SBIR grant from NASA as a sensitive method to assess genomic structural changes caused by exposure to ionizing deep space radiation. Kromatid currently provides commercial dGH assays based on that platform for the detection of oncogenic fusions, the discovery of disease-causing variants, the measurement of biological response as a surrogate for radiation dose, and the measurements of structural off-target effects caused by CRISPR-based gene editing.

According to the SBIR grant abstract, the company's goal is to now provide "high-resolution structural rearrangement data to researchers who need to screen larger libraries of samples (oncology), investigate a very diverse patient population (rare diseases), or assay very large numbers of cells for complex rearrangements (gene editing)." The company plans to develop an automated, full-genome dGH screening method comprised of high-density chromatid paints and image processing software that can detect inversions and translocations smaller than 10 kilobases, which can screen both very large numbers of samples and large numbers of cells in individual samples.

"Through this SBIR award, the NIH is making it possible for Kromatid to provide economical, whole-genome analysis in thousands of single cells per sample — enabling the discovery of rare structural variants and the measurement of extremely low levels of off-target structural damage in batches of edited cells," Kromatid President and Chief Technology Officer Christopher Tompkins said in a statement.

The esports surge — and the massive opportunities behind it



31 million people watch esports tournaments in the U.S., and more than double that, 68M, in China. And the question is — how do you monetize that at scale? Don’t miss this VB Live event for keen insights on how U.S. companies can effectively operate globally or begin to expand globally.

Here’s the big esports question: Is there anybody who’s really interested in watching other people play a game as opposed to playing a game themselves? With more than 150 million people a month on Twitch, there really is no question.

Esports, which racked up 300 million viewers worldwide last year, is on track to surpass a billion dollars for the first time this year, across all markets, and not just from indirect revenue sources, like advertising and sponsorship. Merchandise sales, ticket sales, and other items that consumers purchase directly make up about a quarter of that income.

“Blizzard can sell out tickets for its esports tournaments at BlizzCon — these are tickets that go for about $200 a pop, and they sell 25,000 seats in about six seconds,” says Dean Takahashi, lead writer for GamesBeat. “That’s pretty amazing.”

What’s behind the surge? For one, internet infrastructure and bandwidth making live streaming much more viable — and with streaming, you get a much more micro-targeted audience, says Carter Rogers, senior analyst at SuperData Research. Ratings you might sniff at in the TV world are still very viable for esports ecosystems, because the super devoted fans watching on Twitch or YouTube are devoting their time and money to it, making a bigger ecosystem possible.

Games are also getting more fun to watch, Takahashi suggests, with titles like League of Legends, Arena of Valor, Overwatch, Fortnite, and PUBG, and the releases just keep on coming. The esports trend started in the Asian market, almost ten years ahead of the rest of the world, when StarCraft was a thing.

And in China, it’s even getting much closer to a truly mainstream activity, Rogers adds.

“We see games like Honor of Kings or Arena of Valor, which we might think of as very male-focused in the west, with very even gender ratios in their players,” he says. “It’s an activity that reaches across male and female audiences and reaches across age groups.”

However, game tournaments aren’t even the most popular form of gaming video content, despite the big draw. Audiences are stacking up for walkthroughs, game strategy videos, and game trailers.

But no matter what they’re watching, these viewers are extremely engaged, he adds.

“They watch for long periods of time, and they watch live because they want to do things like interact with other fans,” Rogers says. “Esports and live streaming have really brought back live TV viewing, much like real-world sports.”

A big part of the surge is how connected this audience really is, says Johannes Waldstein, CEO of FanAI Inc., which works with esports teams like Cloud9, TSM, Liquid, Optic Gaming, and leagues like the Turner E-League.

“It’s having 90 million people messaging each other on Discord, being on Twitter, being on Twitch,” Waldstein says. “Unlike television, these are the platforms and the places where you have friendships with people you know in real life and with people you know only in the gaming or virtual world.”

Worldpay research estimates that there will be 25 billion connected devices by the year 2020, says Roc Harry, relationship director at Worldpay, and that full-powered mobile devices, which allow users the convenience of streaming anywhere, will continue to drop in cost.

And that’s where much of the opportunity in esports lies, especially in Asia, Rogers says.

“Mobile esports that we wouldn’t consider viable in the west are the norm in Asia,” he explains. “We’re seeing mobile games that have the potential to build a truly hardcore audience.”

Adds Waldstein: “Sponsorship is going to be one of the largest growth areas.”

What they’ve found is that the audience is not as homogenous as everyone assumes, with much more varied cultures, ethnicities, and socioeconomic backgrounds, than you would expect, he says. But it does skew toward the wealthy millennial: Somebody who can afford to go to one of these events, or play competitive games on a higher-end PC.

“You now have some of the big brands and agencies that are not traditionally in esports now suddenly realizing, ‘Wait a second, these audiences block my ads, they don’t watch traditional sports where my advertising budget is typically going, but they have an affinity for my product, they’re the right life stage, they have discretionary spend,'” he says. “This is a good place for me to find and engage with the right type of customer.'”

“Opportunities are breeding more opportunities and attracting more investment into esports now,” Takahashi adds. “I moderated a session a couple of weeks ago at the Milken global conference where there were about 4,000 investors.”

They were all very interested to learn that there are companies like Lionsgate and venture capitalists like Crosscut Ventures investing in teams like the Immortals, he says. Kent Wakeford and Kevin Chou, the former leaders of Kabam, are investing in the company behind the Seoul Dynasty Overwatch team. Tencent, Activision Blizzard, Robert Kraft of the New England Patriots, the owners of the Sacramento Kings, the owners of the New York Mets, the Philadelphia 76ers, and a lot of other traditional sports companies are coming in. Even venue companies like AEG, which owns the Staples Center, are investing in this market.

“It’s those layers of investment that are building up across the whole ecosystem, from the amateur level all the way up to this professional, championship level,” Takahashi says. “That’s what’s really generating a lot of this excitement. It’s breeding more opportunity.”

Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May

Shares of gene editing leaders Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics had an amazing month.

Maxx Chatsko

Jun 8, 2018 at 4:05PM


What happened

It was a great month for shareholders holding any piece of the fledgling field of CRISPR gene editing technologies. Shares of Editas Medicine (NASDAQ:EDIT) rose over 22%, Intellia Therapeutics (NASDAQ:NTLA) gained 33.4%, and CRISPR Therapeutics (NASDAQ:CRSP)jumped an impressive 47.1%, according to data provided by S&P Global Market Intelligence.

What moved these CRISPR stocks higher? Last month all three companies announced first-quarter 2018 financial results and provided updates on their respective drug development efforts. Broadly speaking, investors are excited about the coming initiation of clinical trials -- which will be the first ever for CRISPR drug candidates in the United States -- and are racing to own a piece of the action ahead of expected catalysts. However, there are company-specific factors investors should know.

So what

Since all CRISPR stocks represent development-stage biopharmas, the updates provided during quarterly earnings releases aren't very important from a financial perspective -- with the possible exception of cash balances. Rather, quarterly updates are times for gene-editing companies to announce pipeline and collaboration updates.

With that in mind, Editas Medicine announced that it ended March with $359 million in cash and cash equivalents. The company is barreling toward filing an investigational new drug (IND) application in mid-2018 for its lead drug candidate, EDIT-101, to be evaluated as a possible treatment for Leber's Congenital Amaurosis type 10 (LCA10), an eye disease that impairs vision.

In fact, Editas Medicine presented data later in May on EDIT-101 showing it was well-tolerated in nonhuman primates (which may be the golden standard for getting the first CRISPR drugs into clinical trials), using the same procedure the company plans to use in a phase 1/2 trial in humans. There was also news of an expanded collaboration with Celgene in oncology applications, and more preclinical data was generated for potential treatments in eye and blood diseases.

Intellia Therapeutics announced that it ended March with $328 million in cash and cash equivalents. It was the first full quarter with new CEO Dr. John Leonard at the helm; he was appointed to broaden the clinical strategy, and ensure the company didn't fall behind its peers. The CRISPR pioneer plans to submit an IND for its lead drug candidate, a potential treatment for the rare metabolic disease transthyretin amyloidosis, by the end of 2019.

While that may seem far off, more time is needed to generate data on a novel lipid nanoparticle delivery system (one of the most important parts of a gene-editing therapeutic) and possible dosing regimens. Since there's no blueprint to follow for CRISPR gene-editing therapeutics, it may prove best to walk slowly to avoid costly missteps in the clinic. Additionally, two other rare hereditary diseases showed further progress in preclinical studies, while Intellia Therapeutics also announced its first target for edited immune cells for cell-therapy applications.

Last but not least, CRISPR Therapeutics announced that it ended March with $342 million in cash and cash equivalents. The company expects to begin clinical trials to evaluate its lead drug candidate, CTX001, as a potential treatment for blood disorders such as sickle-cell disease in 2018. Or, it did, but the drug was put on a clinical hold by the U.S. Food and Drug Administration.

There's an argument to be made that the recent slide creates a buying opportunity, especially considering that the "clinical hold" was put in place for an asset that's not even in the clinic yet; nonetheless, CRISPR Therapeutics will look to clear that up. It also expects to file an IND for its second therapeutic asset, CTX101, by the end of 2018; the drug candidate is a CRISPR-edited CAR-T therapeutic designed to target specific markers of B-cell cancers.

Now what

CRISPR stocks were a hot commodity last month, which isn't surprising given all the hype and promise surrounding gene editing. There were also several major clinical conferences for oncology and gene therapy, which helped to keep the pioneering efforts of these companies at the forefront of the market's awareness. So although there's a long way to go before any of these approaches yields a commercial product, investors can expect a volatile -- and perhaps lucrative -- journey through the stock market to continue.